UTHR
United Therapeutics Corporation
Price Chart
Latest Quote
$475.00
Current Price| Previous Close | $469.49 |
| Open | $466.89 |
| Day High | $475.65 |
| Day Low | $466.01 |
| Volume | 351,550 |
Stock Information
| Shares Outstanding | 43.06M |
| Cash Equivalents | $2.77B |
| Revenue | $3.13B |
| Net Income | $1.27B |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Market Cap | $21.48B |
| P/E Ratio | 18.01 |
| EPS (TTM) | $26.38 |
| Exchange | NMS |
📊 Custom Metrics & Score
Score: 33/42| Debt to Equity | 0.05 |
| Debt to Earnings | 0.12 |
| Current Ratio | 5.25 |
| Quick Ratio | 4.80 |
| Avg Revenue Growth | 17.68% |
| Profit Margin | 41.53% |
| Return on Equity | 18.55% |
| Avg FCF Growth | 31.59% |
| FCF Yield | 5.03% |
Score Explanation: The perfect score is 42/42 based on debt levels, profitability, growth rates, and cash flow metrics. FCF Yield is weighted most heavily as it shows what return the business currently generates.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-02-02 | $475.00 | 351,550 |
| 2026-01-30 | $469.49 | 373,200 |
| 2026-01-29 | $467.70 | 260,800 |
| 2026-01-28 | $467.30 | 274,100 |
| 2026-01-27 | $476.78 | 267,300 |
| 2026-01-26 | $473.36 | 352,400 |
| 2026-01-23 | $468.94 | 248,900 |
| 2026-01-22 | $472.06 | 254,000 |
| 2026-01-21 | $469.77 | 326,900 |
| 2026-01-20 | $468.07 | 420,400 |
| 2026-01-16 | $464.93 | 397,700 |
| 2026-01-15 | $471.99 | 292,300 |
| 2026-01-14 | $475.73 | 376,600 |
| 2026-01-13 | $476.86 | 340,200 |
| 2026-01-12 | $482.39 | 391,700 |
| 2026-01-09 | $483.23 | 410,500 |
| 2026-01-08 | $490.83 | 329,800 |
| 2026-01-07 | $503.69 | 302,900 |
| 2026-01-06 | $502.71 | 306,700 |
| 2026-01-05 | $489.69 | 619,700 |
About United Therapeutics Corporation
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company involved in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. United Therapeutics Corporation was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
📰 Latest News
A Look Back at Therapeutics Stocks’ Q3 Earnings: United Therapeutics (NASDAQ:UTHR) Vs The Rest Of The Pack
StockStory • 2026-01-30T03:32:21Z
Therapeutics Stocks Q3 Highlights: United Therapeutics (NASDAQ:UTHR)
StockStory • 2026-01-28T03:33:54Z
How Investors May Respond To United Therapeutics (UTHR) Positive Early Data For Bioengineered Liver Support Device
Simply Wall St. • 2026-01-26T13:07:30Z
United Therapeutics Corporation (UTHR): A Bull Case Theory
Insider Monkey • 2026-01-19T22:17:31Z
3 Market-Beating Stocks to Target This Week
StockStory • 2026-01-16T04:42:20Z
6 stocks and ETFs that these unsung market heroes see outperforming in 2026
MarketWatch • 2026-01-13T15:39:00Z
Reassessing United Therapeutics (UTHR) Valuation After Strong 1 Year Share Price Performance
Simply Wall St. • 2026-01-13T12:09:04Z
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
Zacks • 2026-01-12T14:00:06Z
2 Cash-Heavy Stocks to Target This Week and 1 We Question
StockStory • 2026-01-12T04:35:52Z
UTHR or MDGL: Which Is the Better Value Stock Right Now?
Zacks • 2026-01-08T16:40:05Z
Income Statement (Annual)
Revenue
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Reconciled Cost Of Revenue | $309,700,000 | $257,500,000 | $151,600,000 | $122,500,000 |
| Cost Of Revenue | $309,700,000 | $257,500,000 | $151,600,000 | $122,500,000 |
| Total Revenue | $2,877,400,000 | $2,327,500,000 | $1,936,300,000 | $1,685,500,000 |
| Operating Revenue | $2,877,400,000 | $2,327,500,000 | $1,936,300,000 | $1,685,500,000 |
Expenses
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Interest Expense | $42,900,000 | $59,300,000 | $32,400,000 | $18,600,000 |
| Total Expenses | $1,429,300,000 | $1,142,600,000 | $956,600,000 | $1,129,600,000 |
| Other Income Expense | $-65,300,000 | $-14,000,000 | $-41,900,000 | $39,900,000 |
| Other Non Operating Income Expenses | $5,800,000 | $-14,000,000 | $-40,200,000 | $42,200,000 |
| Net Non Operating Interest Income Expense | $156,200,000 | $103,400,000 | $12,800,000 | $-1,900,000 |
| Interest Expense Non Operating | $42,900,000 | $59,300,000 | $32,400,000 | $18,600,000 |
| Operating Expense | $1,119,600,000 | $885,100,000 | $805,000,000 | $1,007,100,000 |
| Selling And Marketing Expense | $96,300,000 | $81,800,000 | $70,800,000 | $64,400,000 |
| General And Administrative Expense | $542,300,000 | $395,300,000 | $411,300,000 | $402,600,000 |
Income & Earnings
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Income From Continuing Operation Net Minority Interest | $1,195,100,000 | $984,800,000 | $727,300,000 | $475,800,000 |
| Net Interest Income | $156,200,000 | $103,400,000 | $12,800,000 | $-1,900,000 |
| Interest Income | $199,100,000 | $162,700,000 | $45,200,000 | $16,700,000 |
| Normalized Income | $1,250,558,000 | $984,800,000 | $728,609,000 | $477,640,000 |
| Net Income From Continuing And Discontinued Operation | $1,195,100,000 | $984,800,000 | $727,300,000 | $475,800,000 |
| Total Operating Income As Reported | $1,377,000,000 | $1,184,900,000 | $979,700,000 | $555,900,000 |
| Net Income Common Stockholders | $1,195,100,000 | $984,800,000 | $727,300,000 | $475,800,000 |
| Net Income | $1,195,100,000 | $984,800,000 | $727,300,000 | $475,800,000 |
| Net Income Including Noncontrolling Interests | $1,195,100,000 | $984,800,000 | $727,300,000 | $475,800,000 |
| Net Income Continuous Operations | $1,195,100,000 | $984,800,000 | $727,300,000 | $475,800,000 |
| Pretax Income | $1,539,000,000 | $1,274,300,000 | $950,600,000 | $593,900,000 |
| Special Income Charges | $-71,100,000 | $0 | $-1,700,000 | $-2,300,000 |
| Interest Income Non Operating | $199,100,000 | $162,700,000 | $45,200,000 | $16,700,000 |
| Operating Income | $1,448,100,000 | $1,184,900,000 | $979,700,000 | $555,900,000 |
| Gross Profit | $2,567,700,000 | $2,070,000,000 | $1,784,700,000 | $1,563,000,000 |
Per Share Metrics
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Diluted EPS | $24.64 | $19.81 | $15.00 | $10.06 |
| Basic EPS | $26.44 | $21.04 | $15.98 | $10.60 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Tax Effect Of Unusual Items | $-15,642,000 | $0 | $-391,000 | $-460,000 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $1,725,500,000 | $1,386,800,000 | $1,036,000,000 | $664,700,000 |
| Total Unusual Items | $-71,100,000 | $0 | $-1,700,000 | $-2,300,000 |
| Total Unusual Items Excluding Goodwill | $-71,100,000 | $0 | $-1,700,000 | $-2,300,000 |
| Reconciled Depreciation | $72,500,000 | $53,200,000 | $51,300,000 | $49,900,000 |
| EBITDA (Bullshit earnings) | $1,654,400,000 | $1,386,800,000 | $1,034,300,000 | $662,400,000 |
| EBIT | $1,581,900,000 | $1,333,600,000 | $983,000,000 | $612,500,000 |
| Diluted Average Shares | $48,500,000 | $49,700,000 | $48,500,000 | $47,300,000 |
| Basic Average Shares | $45,200,000 | $46,800,000 | $45,500,000 | $44,900,000 |
| Diluted NI Availto Com Stockholders | $1,195,100,000 | $984,800,000 | $727,300,000 | $475,800,000 |
| Tax Provision | $343,900,000 | $289,500,000 | $223,300,000 | $118,100,000 |
| Other Special Charges | $71,100,000 | - | - | - |
| Write Off | $0 | $0 | $1,700,000 | $2,300,000 |
| Research And Development | $481,000,000 | $408,000,000 | $322,900,000 | $540,100,000 |
| Selling General And Administration | $638,600,000 | $477,100,000 | $482,100,000 | $467,000,000 |
| Other Gand A | $432,800,000 | $374,200,000 | $333,200,000 | $294,300,000 |
| Salaries And Wages | $109,500,000 | $21,100,000 | $78,100,000 | $108,300,000 |
Balance Sheet (Annual)
Assets
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Tangible Assets | $6,332,100,000 | $5,870,600,000 | $4,752,200,000 | $3,914,300,000 |
| Total Assets | $7,364,000,000 | $7,167,000,000 | $6,044,500,000 | $5,169,100,000 |
| Total Non Current Assets | $3,490,100,000 | $3,616,000,000 | $2,664,200,000 | $2,845,500,000 |
| Other Non Current Assets | $222,100,000 | $151,800,000 | $114,300,000 | $108,200,000 |
| Non Current Deferred Assets | $458,400,000 | $394,800,000 | $327,700,000 | $261,900,000 |
| Non Current Deferred Taxes Assets | $458,400,000 | $394,800,000 | $327,700,000 | $261,900,000 |
| Investmentin Financial Assets | $1,475,300,000 | $1,909,800,000 | - | - |
| Goodwill And Other Intangible Assets | $111,900,000 | $114,200,000 | $44,500,000 | $44,600,000 |
| Other Intangible Assets | $79,600,000 | $80,500,000 | $16,500,000 | $16,600,000 |
| Current Assets | $3,873,900,000 | $3,551,000,000 | $3,380,300,000 | $2,323,600,000 |
| Other Current Assets | $169,700,000 | $166,200,000 | $219,200,000 | $100,400,000 |
| Inventory | $157,900,000 | $111,800,000 | $102,000,000 | $93,800,000 |
| Receivables | $279,300,000 | $278,900,000 | $220,400,000 | $198,700,000 |
| Accounts Receivable | $279,300,000 | $278,900,000 | $220,400,000 | $198,700,000 |
| Cash Cash Equivalents And Short Term Investments | $3,267,000,000 | $2,994,100,000 | $2,838,700,000 | $1,930,700,000 |
| Cash And Cash Equivalents | $1,697,200,000 | $1,207,700,000 | $961,200,000 | $894,800,000 |
Debt
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Debt | $300,000,000 | $700,000,000 | $800,000,000 | $800,000,000 |
| Current Debt And Capital Lease Obligation | $300,000,000 | $400,000,000 | - | - |
| Current Debt | $300,000,000 | $400,000,000 | - | - |
| Other Current Borrowings | $300,000,000 | $400,000,000 | - | - |
| Long Term Debt And Capital Lease Obligation | - | $300,000,000 | $800,000,000 | $800,000,000 |
| Long Term Debt | - | $300,000,000 | $800,000,000 | $800,000,000 |
Liabilities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Liabilities Net Minority Interest | $920,000,000 | $1,182,200,000 | $1,247,800,000 | $1,210,200,000 |
| Total Non Current Liabilities Net Minority Interest | $181,900,000 | $377,800,000 | $904,600,000 | $904,800,000 |
| Other Non Current Liabilities | $181,900,000 | $77,800,000 | $104,600,000 | $104,800,000 |
| Current Liabilities | $738,100,000 | $804,400,000 | $343,200,000 | $305,400,000 |
| Other Current Liabilities | $82,600,000 | $71,000,000 | $32,500,000 | $28,400,000 |
| Payables And Accrued Expenses | $344,500,000 | $298,000,000 | $229,900,000 | $174,600,000 |
| Payables | $6,000,000 | $5,600,000 | $4,100,000 | $3,800,000 |
| Accounts Payable | $6,000,000 | $5,600,000 | $4,100,000 | $3,800,000 |
Equity
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Common Stock Equity | $6,444,000,000 | $5,984,800,000 | $4,796,700,000 | $3,958,900,000 |
| Total Equity Gross Minority Interest | $6,444,000,000 | $5,984,800,000 | $4,796,700,000 | $3,958,900,000 |
| Stockholders Equity | $6,444,000,000 | $5,984,800,000 | $4,796,700,000 | $3,958,900,000 |
| Gains Losses Not Affecting Retained Earnings | $-3,400,000 | $-12,800,000 | $-55,500,000 | $-23,000,000 |
| Other Equity Adjustments | $-3,400,000 | $-12,800,000 | $-55,500,000 | $-23,000,000 |
| Retained Earnings | $7,222,200,000 | $6,027,100,000 | $5,042,300,000 | $4,315,000,000 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Treasury Shares Number | $30,166,590 | $26,619,216 | $26,619,216 | $26,619,216 |
| Ordinary Shares Number | $44,831,306 | $47,040,545 | $46,032,064 | $45,107,805 |
| Share Issued | $74,997,896 | $73,659,761 | $72,651,280 | $71,727,021 |
| Tangible Book Value | $6,332,100,000 | $5,870,600,000 | $4,752,200,000 | $3,914,300,000 |
| Invested Capital | $6,744,000,000 | $6,684,800,000 | $5,596,700,000 | $4,758,900,000 |
| Working Capital | $3,135,800,000 | $2,746,600,000 | $3,037,100,000 | $2,018,200,000 |
| Total Capitalization | $6,444,000,000 | $6,284,800,000 | $5,596,700,000 | $4,758,900,000 |
| Treasury Stock | $3,474,500,000 | $2,579,200,000 | $2,579,200,000 | $2,579,200,000 |
| Additional Paid In Capital | $2,698,900,000 | $2,549,000,000 | $2,388,400,000 | $2,245,400,000 |
| Capital Stock | $800,000 | $700,000 | $700,000 | $700,000 |
| Common Stock | $800,000 | $700,000 | $700,000 | $700,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Pensionand Other Post Retirement Benefit Plans Current | $11,000,000 | $35,400,000 | $80,800,000 | $102,400,000 |
| Current Accrued Expenses | $338,500,000 | $292,400,000 | $225,800,000 | $170,800,000 |
| Investments And Advances | $1,475,300,000 | $1,909,800,000 | $1,316,200,000 | $1,649,900,000 |
| Available For Sale Securities | $1,475,300,000 | $1,909,800,000 | - | - |
| Goodwill | $32,300,000 | $33,700,000 | $28,000,000 | $28,000,000 |
| Net PPE | $1,222,400,000 | $1,045,400,000 | $861,500,000 | $780,900,000 |
| Accumulated Depreciation | $-491,200,000 | $-428,200,000 | $-382,700,000 | $-342,400,000 |
| Gross PPE | $1,713,600,000 | $1,473,600,000 | $1,244,200,000 | $1,123,300,000 |
| Construction In Progress | $218,200,000 | $259,100,000 | $110,900,000 | $55,100,000 |
| Machinery Furniture Equipment | $449,700,000 | $381,200,000 | $353,900,000 | $322,900,000 |
| Buildings And Improvements | $863,800,000 | $685,300,000 | $636,700,000 | $612,700,000 |
| Land And Improvements | $181,900,000 | $148,000,000 | $142,700,000 | $132,600,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $95,000,000 | $55,700,000 | $50,700,000 | $44,300,000 |
| Work In Process | $34,300,000 | $34,400,000 | $33,300,000 | $31,900,000 |
| Raw Materials | $28,600,000 | $21,700,000 | $18,000,000 | $17,600,000 |
| Other Short Term Investments | $1,569,800,000 | $1,786,400,000 | $1,877,500,000 | $1,035,900,000 |
Cash Flow Statement (Annual)
Free Cash Flow
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | $1,080,600,000 | $747,600,000 | $663,700,000 | $477,400,000 |
Operating Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Operating Cash Flow | $1,327,100,000 | $978,000,000 | $802,500,000 | $598,200,000 |
| Cash Flow From Continuing Operating Activities | $1,327,100,000 | $978,000,000 | $802,500,000 | $598,200,000 |
| Operating Gains Losses | - | - | $-7,100,000 | $-92,600,000 |
Investing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Capital Expenditure | $-246,500,000 | $-230,400,000 | $-138,800,000 | $-120,800,000 |
| Investing Cash Flow | $417,200,000 | $-719,600,000 | $-811,500,000 | $-486,900,000 |
| Cash Flow From Continuing Investing Activities | $417,200,000 | $-719,600,000 | $-811,500,000 | $-486,900,000 |
| Net Other Investing Changes | $-28,500,000 | $-23,000,000 | $3,500,000 | - |
Financing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Repurchase Of Capital Stock | $-1,012,200,000 | $-13,800,000 | $-11,400,000 | $-10,800,000 |
| Financing Cash Flow | $-1,254,800,000 | $-11,900,000 | $75,400,000 | $44,800,000 |
| Cash Flow From Continuing Financing Activities | $-1,254,800,000 | $-11,900,000 | $75,400,000 | $44,800,000 |
| Net Other Financing Charges | $-2,700,000 | $-2,700,000 | $-7,500,000 | - |
| Net Common Stock Issuance | $-1,012,200,000 | $-13,800,000 | $-11,400,000 | $-10,800,000 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Repayment Of Debt | $-400,000,000 | $-100,000,000 | $-800,000,000 | $0 |
| Issuance Of Debt | $0 | $0 | $800,000,000 | $0 |
| Interest Paid Supplemental Data | $40,200,000 | $56,000,000 | $29,100,000 | $16,200,000 |
| Income Tax Paid Supplemental Data | $400,600,000 | $332,500,000 | $275,700,000 | $153,300,000 |
| End Cash Position | $1,697,200,000 | $1,207,700,000 | $961,200,000 | $894,800,000 |
| Beginning Cash Position | $1,207,700,000 | $961,200,000 | $894,800,000 | $738,700,000 |
| Changes In Cash | $489,500,000 | $246,500,000 | $66,400,000 | $156,100,000 |
| Proceeds From Stock Option Exercised | $160,100,000 | $104,600,000 | $94,300,000 | $55,600,000 |
| Common Stock Payments | $-1,012,200,000 | $-13,800,000 | $-11,400,000 | $-10,800,000 |
| Net Issuance Payments Of Debt | $-400,000,000 | $-100,000,000 | $0 | $0 |
| Net Short Term Debt Issuance | $-400,000,000 | $-100,000,000 | $0 | $0 |
| Short Term Debt Payments | $-400,000,000 | $-100,000,000 | $-800,000,000 | $0 |
| Short Term Debt Issuance | $0 | $0 | $800,000,000 | $0 |
| Net Investment Purchase And Sale | $722,700,000 | $-377,000,000 | $-674,700,000 | $-366,100,000 |
| Sale Of Investment | $2,368,800,000 | $2,137,300,000 | $1,033,900,000 | $1,529,200,000 |
| Purchase Of Investment | $-1,646,100,000 | $-2,514,300,000 | $-1,708,600,000 | $-1,895,300,000 |
| Net Business Purchase And Sale | $-30,500,000 | $-89,200,000 | $-1,500,000 | $0 |
| Purchase Of Business | $-30,500,000 | $-89,200,000 | $-1,500,000 | $0 |
| Net PPE Purchase And Sale | $-246,500,000 | $-230,400,000 | $-138,800,000 | $-120,800,000 |
| Purchase Of PPE | $-246,500,000 | $-230,400,000 | $-138,800,000 | $-120,800,000 |
| Change In Working Capital | $-60,200,000 | $-97,800,000 | $-141,200,000 | $-174,200,000 |
| Change In Other Working Capital | $-55,600,000 | $-82,800,000 | $-150,600,000 | $-112,900,000 |
| Change In Payables And Accrued Expense | $42,700,000 | $57,100,000 | $44,500,000 | $-12,500,000 |
| Change In Inventory | $-46,900,000 | $-13,600,000 | $-13,400,000 | $-7,500,000 |
| Change In Receivables | $-400,000 | $-58,500,000 | $-21,700,000 | $-41,300,000 |
| Changes In Account Receivables | $-400,000 | $-58,500,000 | $-21,700,000 | $-41,300,000 |
| Other Non Cash Items | $-24,300,000 | $-4,900,000 | $52,500,000 | $65,900,000 |
| Stock Based Compensation | $144,000,000 | $39,100,000 | $106,800,000 | $138,500,000 |
| Asset Impairment Charge | $0 | $3,600,000 | $12,900,000 | $134,900,000 |
| Depreciation Amortization Depletion | $72,500,000 | $53,200,000 | $51,300,000 | $49,900,000 |
| Depreciation And Amortization | $72,500,000 | $53,200,000 | $51,300,000 | $49,900,000 |
| Amortization Cash Flow | $900,000 | $300,000 | $100,000 | $100,000 |
| Amortization Of Intangibles | $900,000 | $300,000 | $100,000 | $100,000 |
| Depreciation | $71,600,000 | $52,900,000 | $51,200,000 | $49,800,000 |
| Net Income From Continuing Operations | $1,195,100,000 | $984,800,000 | $727,300,000 | $475,800,000 |
| Net Long Term Debt Issuance | - | - | $0 | $0 |
| Long Term Debt Payments | - | - | $-800,000,000 | $0 |
| Long Term Debt Issuance | - | - | $800,000,000 | $0 |
| Sale Of Business | - | - | $8,600,000 | $0 |
| Sale Of PPE | - | - | $0 | $0 |
| Gain Loss On Investment Securities | - | - | $-7,100,000 | $-92,600,000 |